SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with n ...

Group 1: Appointment of Dr. Andreas Niethammer - OSR Holdings, Inc. has appointed Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, focusing on the development of orally administered T-cell activators, including VXM01, an anti-VEGFR-2 candidate in clinical stages [1][2] - Dr. Niethammer is an internationally recognized expert in oncology with over 20 years of experience in cancer immunotherapy and clinical development, having held leadership roles in several global biopharmaceutical companies [2][4] Group 2: Vaximm AG and its Focus - Vaximm AG, a wholly owned subsidiary of OSR Holdings, is a Swiss-German biotech company dedicated to developing oral T-cell immunotherapies for cancer, with its lead program VXM01 having completed Phase I/II clinical trials for pancreatic cancer and glioblastoma [5][6] - The company aims to activate targeted cytotoxic T-cell responses through oral administration, representing a novel approach in cancer treatment [5] Group 3: Future Directions and Vision - Dr. Niethammer expressed optimism about accelerating the development of oral immunotherapies with the potential to improve outcomes for patients with challenging cancers and other diseases with high unmet needs [4] - OSR Holdings envisions acquiring and operating a portfolio of innovative healthcare companies to enhance patient care through advanced research and development [6]

Core Viewpoint - The GLP-1 drug revolution continues to thrive in the first half of 2025, with Novo Nordisk's Wegovy and Eli Lilly's Zepbound emerging as star products, driving significant capital interest in the industry [2] Group 1: Omada Health - Omada Health, established in 2011, went public on June 6, 2025, at a price of $19 per share, raising approximately $150 million [3] - The stock surged to a high of $28 on its first day, closing at $23, marking a 21% increase and elevating the company's valuation to about $1.28 billion [3] - In 2024, Omada reported revenues of $169.8 million, a 38% year-over-year increase, with a gross margin of 60.6% [3] - By Q1 2025, revenues soared to $55 million, a 57% increase, while net losses decreased from $19 million to $9.4 million [3] - Omada's business model focuses on charging enterprises, health plans, and insurance channels for ongoing remote management services, filling the gap in health management between in-person visits [4] Group 2: Metsera - Metsera, founded in 2022, completed its IPO in January 2025 at $18 per share, raising $275 million [5] - The stock closed at $26.50 on its first day, reflecting a 47% increase, with an early high of over $35 [5] - Metsera's market capitalization was previously under $2 billion, but it is viewed as a strong contender in the anti-obesity sector [6] Group 3: Pipeline and Clinical Highlights - Metsera's lead product, MET-097i, is a long-acting GLP-1 receptor agonist showing promising results in early clinical trials, with an average weight loss of 11.3% over 12 weeks [7] - The drug demonstrates potential for monthly dosing, with a longer duration of action compared to competitors like Zepbound and Ozempic [7] - MET-233i, another product from Metsera, shows advantages in weight loss and pharmacokinetics, supporting monthly dosing [8] - Metsera's cash reserves post-IPO are approximately $590 million, ensuring operational sustainability until 2027 [9] Group 4: Industry Landscape - Other companies are also pursuing opportunities in the GLP-1 space, including Aardvark Therapeutics and BioAge Labs, which are building IPO frameworks and advancing their core pipelines [11][12] - The GLP-1 ecosystem is characterized by diverse technological pathways, providing investors with various options [14] Group 5: Investment Enthusiasm - The GLP-1 market is projected to exceed $100 billion by 2030, attracting significant investor interest [15] - Companies like Metsera and Omada are seen as having competitive advantages, such as long-acting formulations and extensive digital platforms [15] - Clinical milestones, such as Phase 3 trial initiations, are expected to act as catalysts for stock price increases [15]

Aardvark Therapeutics (AARD) Conference Call Summary Company Overview - Aardvark Therapeutics is a publicly traded company based in San Diego, California, focusing on developing oral small molecule drugs targeting bitter taste receptors to influence gut-brain signaling pathways related to hunger and appetite [2][3] Clinical Programs - The most advanced program is for Prader Willi syndrome, currently in a pivotal phase three trial with expected readout in early 2026 [4] - Plans to initiate a phase two program for hypothalamic obesity and advance another formulation, ARD 201, for general obesity [4][18] Drug Mechanism and Differentiation - Aardvark's drug targets hunger rather than appetite, differentiating it from GLP-1 drugs, which primarily suppress appetite [5][7] - The drug works through gut-brain pathways, reducing ghrelin levels, which is contrary to the effect of GLP-1 treatments that can increase ghrelin [8][20] - The company believes that CCK deficiency contributes to symptoms of Prader Willi syndrome and general obesity, which their drug aims to address [9] Clinical Data and Efficacy - In the phase two trial for Prader Willi syndrome, patients showed an average reduction of 30% in hyperphagia scores (HQCT) over a 28-day dosing period [12][14] - A subgroup of patients with similar features to those expected in the phase three trial experienced a 48% reduction in HQCT, indicating a high probability of success for the upcoming trial [15] - The drug has shown a favorable safety profile, with no adverse events exceeding grade two reported in over 70 patients dosed [11] Future Trials and Endpoints - The phase three trial will include a randomized, placebo-controlled design with primary endpoints focused on HQCT scores at week twelve [15][16] - Secondary endpoints will assess clinical global impression, body composition, inflammatory biomarkers, and ghrelin levels [16] Additional Programs - The hypothalamic obesity program is set to leverage similarities with Prader Willi syndrome, targeting patients with overactive hunger due to prior interventions [17] - The ARD 201 program aims to combine ARD 101 with a TPD4 inhibitor, enhancing its efficacy for general obesity while being cautious of its use in Prader Willi syndrome due to potential risks [18] Market Potential - There are approximately 10,000 to 25,000 patients in the U.S. with Prader Willi syndrome, with a global occurrence rate of 1 in 15,000 live births, suggesting a significant market opportunity [10] - The company aims to demonstrate additive benefits of their drug on top of existing GLP-1 therapies, potentially appealing to a broader patient population [20][22] Summary - Aardvark Therapeutics is strategically positioned with a unique approach to treating hunger-related conditions, backed by promising clinical data and a robust pipeline of programs targeting rare and general obesity [22]